These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1506732)

  • 1. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
    Usui N; Suzuki M; Takada M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
    Yakushiji M; Nishimura H
    Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
    Oishi T; Maruo T; Iwasaki M; Mochizuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA54/61 as a marker for epithelial ovarian cancer.
    Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
    Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
    Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
    Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CA-125 antigen].
    Zakrzewska I
    Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of biological markers in the diagnosis and monitoring of cystadenocarcinoma].
    Bidart JM; Bellet D
    Rev Prat; 1989 Nov; 39(26):2317-20. PubMed ID: 2595221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis of ovarian tumor by measuring tumor markers].
    Fukatsu T; Nakashima N; Takeuchi J
    Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
    Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
    Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
    Kuzuya K; Nozaki M; Chihara T
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
    Shi W; Zhang YJ; Jiang CY
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New technology of diagnosis of ovarian cancer].
    Terashima Y
    Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
    Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.